|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Three types of lymphoid cancer cells with wild‑type (WT), knockout of miR‑17‑92 (KO), and overexpression of miR‑17‑92 (TG), were utilized to establish a tumor xenograft model, and a reactive hyperplasia lymph cell was used as a control.
|
31322189 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The miR-17-92 cluster is therefore expected not only to be a tumor marker, but also to perform an important role in the early diagnosis of those diseases and possibly also be a target for tumor biotherapy.
|
30854399 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Significantly higher levels were found in high grade tumors for miR-17-5p (p = 0.006), miR-20a-5p (p = 0.007), miR-106b-5p (p = 0.007), miR-93-5p (p = 0.007) and miR-25-3p (p = 0.015) from the paralogous clusters miR-17-92 and miR-106b-25.
|
31581940 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, miR-17-5p, one of the transcribed miRNAs from MIR17HG, reduced the expression of the tumor suppressor B-cell linker (BLNK), resulting in increased migration and invasion of colorectal cancer cells.
|
31409641 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Associations between miR-17/92 and histopathological features were analyzed using general linear models and tumor cell adjusted expression intensities. miR-17-3p and miR-92a were significantly higher expressed in the invasive front of tumors with LNM compared to those without, corresponding to 1.53-fold higher expression of miR-17-3p (95%CI: 1.04-2.24, P = .030) and 1.28-fold higher expression of miR-92a (95%CI: 1.01-1.68, P = .042).
|
29902577 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This positive association of miR-17/92 with BCR-FGFR1 was also confirmed in primary mouse SCLL tissues and primary human CLL samples. miR-17/92 promotes cell proliferation and survival by targeting CDKN1A and PTEN in B-lymphoma cell lines and primary tumors.
|
29367757 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This study uncovers FLI1 as an important driving factor that promotes tumor growth in SCLC through the miR-17-92 pathway.
|
28410216 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The role of miR-17-92 cluster in the expression of tumor suppressor genes in unrestricted somatic stem cells.
|
28222938 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of oncogenic miR-17-92 and tumor suppressive miR-143-145 clusters in basal cell carcinoma and cutaneous squamous cell carcinoma.
|
28187958 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Considering the growing interest in the field of miR‑17‑92 research, we herein review recent advances in the expression and regulation of this cluster in various cancer cells, discuss the proposed mechanism of action for tumorigenesis and tumor development, and propose clinical and therapeutic applications for miR‑17‑92 cluster members, such as potential cancer biomarkers.
|
29039606 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To better understand the prognostic and therapeutic roles of microRNAs in ESCC, we reviewed the diagnosis and prognosis associated oncogenic microRNAs (e.g. miR-21 and miR-17-92 cluster) and tumor suppressor microRNAs (e.g. miR-375, miR-133a and miR-133b), and diagnosis and prognosis associated oncogenic target genes (e.g.
|
28269750 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Together, these findings indicate that SLU7 is co-opted by HCC cells and other tumor cell types to maintain survival, and identify this splicing regulator as a new determinant for the expression of the oncogenic miR-17-92 cluster.
|
26804174 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We mapped the metabolic control element of miR-17∼92 to the miR-17 seed family, which influences cellular metabolism and mammalian target of rapamycin complex 1 (mTORC1) signaling through negative regulation of the LKB1 tumor suppressor. miR-17-dependent tuning of LKB1 levels regulates both the metabolic potential of Myc(+) lymphomas and tumor growth in vivo.
|
27498867 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
By analyzing the miRNA and mRNA sequencing data from the 312 hepatocellular cancer patients available from the TCGA database, we observed that the expression levels of the miR-17-92 cluster members and host gene in the tumor tissues are negatively correlated with several target genes, including CREBL2, PRRG1, NTN4.
|
26233958 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The miR-17∼92. or oncomiR-1, cluster encodes oncogenic microRNAs (miRNAs), and it also promotes retinoblastoma (RB) tumor formation.
|
25513843 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The first identified oncomiR, miR-17-92, is frequently overexpressed in a variety of cancers and its targets include the tumor suppressor PTEN.
|
24469837 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Messenger RNAs of tumor suppressor proteins, such as pRB, PTEN, and Dicer, are targets of miR-17-92 cluster.
|
25140305 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MiR-17-92 cluster has recently been reported as an oncogene in some tumors.
|
24657544 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Accumulative evidence has confirmed that, miR-17-92, a typical polycistronic mRNA cluster, was up-regulated in various solid tumors, and play an important role in the occurrence and development progress of tumors.
|
24824927 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Copy number gain of MIR17HG gene (13q31.3) was rare, with an overall frequency of 2% in gastric cancers (1 of 51). miR-17 knockdown suppressed the monolayer and anchorage-independent growth of FGFR2-amplified KATO-III gastric cancer cells. mir-17-92 TG/TG mice overexpressing the mir-17-92 cluster under the villin promoter developed spontaneous benign tumors in the intestinal tract (log-rank P for tumor-free survival = 0.069).
|
25047501 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The possibility of functional interactions between EZH2 and ZBTB4 was investigated in breast cancer cells and the results showed that EZH2 is directly suppressed by ZBTB4 which in turn is regulated (suppressed) by miR-106b and other paralogues from the miR-17-92, miR-106b-25 and miR-106a-363 clusters that are highly expressed in breast and other tumors.
|
25499219 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Consistent with that idea, miR-15a/16-1 is known to regulate Bcl2 in chronic lymphocytic leukemia, and miR-17-92 regulates the tumor suppressors p21, Pten and Bim in aggressive B-cell lymphomas.
|
23551855 |
2013 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
The mir-17-92 miRNA is among the best characterized miRNA oncogenes, whose genomic amplification or aberrant elevation are frequently observed in a variety of tumor types.
|
23550645 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Real-time quantitative reverse transcriptase PCR was performed to study the expression of the miR 17-92 cluster in primary RB tumors and in Y79 cells after epithelial cell adhesion molecule (EpCAM) silencing.
|
22969266 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Focusing only on miRNAs that were deregulated in the majority of osteosarcoma cell lines, we identified several miRNAs with oncogenic and tumor suppressor properties, including various members of the oncogenic miR-17-92 cluster.
|
22682620 |
2012 |